Table 6.
Prior cytotoxic therapies
| Therapy | Patients (N = 168) |
|---|---|
| Cyclophosphamide | 132 (78.6) |
| Paclitaxel | 108 (64.3) |
| Doxorubicin | 94 (56.0) |
| Docetaxel | 86 (51.2) |
| Capecitabine | 79 (47.0) |
| Fluorouracil | 38 (22.6) |
| Carboplatin | 36 (21.4) |
| Epirubicin | 34 (20.2) |
| Trastuzumab | 30 (17.9) |
| Bevacizumab | 29 (17.3) |
| Everolimus | 26 (15.5) |
| Nab-paclitaxel | 24 (14.3) |
| Gemcitabine | 19 (11.3) |
| Gemcitabine hydrochloride | 17 (10.1) |
| Eribulin | 16 (9.5) |
| Pegylated liposomal doxorubicin hydrochloride | 16 (9.5) |
| Methotrexate | 12 (7.1) |
| Vinorelbine tartrate | 10 (6.0) |
| Cyclophosphamide with doxorubicin | 9 (5.4) |
| Lapatinib | 7 (4.2) |
| Pertuzumab | 7 (4.2) |
| Cisplatin | 6 (3.6) |
| Trastuzumab emtansine | 6 (3.6) |
| Vinorelbine | 6 (3.6) |
| Eribulin mesylate | 3 (1.8) |
| Ixabepilone | 3 (1.8) |
| Cisplatin with docetaxel | 2 (1.2) |
| Cyclophosphamide with docetaxel/doxorubicin | 2 (1.2) |
| Cyclophosphamide with epirubicin hydrochloride/fluorouracil | 2 (1.2) |
| Cyclophosphamide with fluorouracil/methotrexate | 2 (1.2) |
| Doxorubicin hydrochloride | 2 (1.2) |
| Onartuzumab | 2 (1.2) |
| Veliparib | 2 (1.2) |
| PI3 kinase inhibitor | 2 (1.2) |
| Doxorubicin/cyclophosphamide and paclitaxel | 1 (0.6) |
| Carboplatin with gemcitabine | 1 (0.6) |
| Cetuximab | 1 (0.6) |
| 5-Fluorouracil, epirubicin, and cyclophosphamide | 1 (0.6) |
| Cyclophosphamide with epirubicin/fluorouracil | 1 (0.6) |
| Epirubicin hydrochloride | 1 (0.6) |
| Idarubicin | 1 (0.6) |
| Irinotecan | 1 (0.6) |
| Lapatinib ditosylate monohydrate | 1 (0.6) |
| Neratinib | 1 (0.6) |
| Olaparib | 1 (0.6) |
| Panitumumab | 1 (0.6) |
| Ruxolitinib | 1 (0.6) |
| Sorafenib | 1 (0.6) |